BioCentury | Dec 9, 2013
Clinical News

Brovana: Phase III data

...III trial in 841 patients with moderate to severe COPD showing that twice-daily 15 µg Brovana...
...of patients treated with Brovana had >=1 primary endpoint event vs. 15% for placebo. Additionally, Brovana...
...in patients with COPD. Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan Product: Brovana ( arformoterol tartrate...
BioCentury | Sep 3, 2012
Company News

Elevation Pharmaceuticals, Dainippon Sumitomo deal

...will complement its marketed respiratory portfolio, which includes asthma drug Alvesco ciclesonide, COPD treatment Brovana arformoterol tartrate...
BioCentury | Aug 31, 2012
Company News

Sunovion to acquire Elevation

...will complement its marketed respiratory portfolio, which includes asthma drug Alvesco ciclesonide, COPD treatment Brovana arformoterol tartrate...
BioCentury | Mar 31, 2008
Analyst Picks & Changes

Analyst picks & changes

...seasonal allergic rhinitis and Alvesco HFA ciclesonide, an inhaled corticosteroid to treat asthma, will move Brovana...
...hopes to launch the drugs this spring and next half, respectively (see BioCentury, Feb. 4). Brovana...
BioCentury | Jan 7, 2008
Finance

Post-launch report

...$603.0 Schering-Plough (NYSE:SGP) Noxafil posaconazole Prevent invasive Aspergillus and Candida infections U.S. $60.0 Sepracor (NASDAQ:SEPR) Brovana...
BioCentury | Nov 12, 2007
Clinical News

Brovana arformoterol tartrate regulatory update

...Services (CMS) assigned a product-specific billing code under the Medicare Part B benefit for Brovana arformoterol tartrate...
...will be 106% of its average selling price. Sepracor Inc. (SEPR), Marlborough, Mass. Product: Brovana arformoterol tartrate...
BioCentury | Oct 29, 2007
Clinical News

Brovana arformoterol tartrate pulmonary data

...In a 4-week, double-blind study in 215 patients, Brovana did not prolong the QTc interval. Patients...
...of 5, 10 or 25 µg Brovana or placebo for 2 weeks, followed by once-daily Brovana...
...SEPR markets Brovana as maintenance therapy for COPD. Sepracor Inc. (SEPR), Marlborough, Mass. Product: Brovana arformoterol tartrate...
BioCentury | Oct 29, 2007
Clinical News

Brovana arformoterol tartrate: Phase II data

...In an open-label Phase II trial in 39 patients, 15 µg of Brovana showed improvements in...
...SEPR markets Brovana as maintenance therapy for COPD. Sepracor Inc. (SEPR), Marlborough, Mass. Product: Brovana arformoterol tartrate...
BioCentury | Jun 25, 2007
Regulation

Shortness of breath

...markets insomnia drug Lunesta eszopiclone, which had sales of $566.8 million in 2006, and Brovana arformoterol tartrate...
...maintenance treatment of chronic obstructive pulmonary disease (COPD). A CMS reimbursement decision is expected for Brovana...
BioCentury | Apr 16, 2007
Company News

Sepracor sales and marketing update

...SEPR launched Brovana arformoterol tartrate inhalation solution, a twice-daily, long-term maintenance treatment for chronic obstructive pulmonary disease...
Items per page:
1 - 10 of 25